Bioavailability of valsartan oral dosage forms

  title={Bioavailability of valsartan oral dosage forms},
  author={G. Sunkara and G. Bende and A. Mendonza and S. Solar-Yohay and S. Biswal and S. Neelakantham and R. Wagner and J. Flarakos and Yiming Zhang and V. Jarugula},
  journal={Clinical Pharmacology in Drug Development},
The oral bioavailability of valsartan from extemporaneous suspension and solution formulations were evaluated relative to tablet formulation in two separate open‐label, randomized crossover studies in healthy adults. In both studies, the plasma concentrations of valsartan after oral administration were analyzed using validated liquid chromatography‐tandem mass spectrometry (LC–MS/MS) methods, and the corresponding pharmacokinetic parameters were estimated using noncompartmental analysis. The… Expand
Paediatric Medicines: Formulation Considerations
A lack of medicines for children and the impact of paediatric Regulation after ten years of publication, and an increasing number of new paediatric products and new Paediatric Medicines: Formulation Considerations. Expand
MOF Capacitates Cyclodextrin to Mega-Load Mode for High-Efficient Delivery of Valsartan
The new understanding of drug nanoclusters in CD-MOF will help to design more efficient drug delivery systems using CD- MOF carrier with nanocavities. Expand
Integrated Analytical Quality by Design (AQbD) Approach for the Development and Validation of Bioanalytical Liquid Chromatography Method for Estimation of Valsartan.
Significant merits of AQbD approach for holistic process understanding and analytical method development and validation with enhanced robustness and performance are demonstrated. Expand


Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man
The pharmacokinetics of orally and intravenously administered valsartan were determined in two studies and it was found that absorption appeared to follow two first-order processes. Expand
Pharmacokinetics of Valsartan in Pediatric and Adolescent Subjects With Hypertension
Dose‐normalized maximum plasma concentration and area under the plasma‐concentration curve and body weight—normalized apparent oral clearance are comparable for the 4 groups, and major pharmacokinetic parameters are dose normalized for comparison across the age groups. Expand
Pharmacokinetics, disposition and biotransformation of [14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose.
The disposition of valsartan, a potent angiotensin II receptor antagonist, was investigated in six healthy male volunteers and it was indicated that at least 51% of the dose was absorbed. Expand
Population pharmacokinetics of valsartan in pediatrics.
The population pharmacokinetic model reveals that increase in age has minimal influence on body size dependent clearance of valsartan in children. Expand
The effect of age on the pharmacokinetics of valsartan
Variability, as shown by the coefficient of variation (CV), was larger for the elderly subjects and ANOVA of the log transformed AUC showed a significant difference between the two groups, but this difference is not sufficient to warrant initial dose adjustment based on age per se. Expand
Pharmacokinetics of Multiple Doses of Valsartan in Patients With Heart Failure
Results showed that the mean area under the concentration-time curve (AUC) and maximum concentration (Cmax) increased in a linear and nearly proportional manner with valsartan dose, and the pharmacokinetic values were higher in heart failure patients than in healthy volunteers. Expand
Pharmacokinetics of valsartan in patients with liver disease
To determine the exposure to valsartan when liver function is impaired, a pharmacokinetic study was performed in patients with mild and moderate impairment of liver function and to characterize the compound(s) excreted in the bile. Expand
Clinical utility of valsartan in the treatment of hypertension in children and adolescents
Current studies have not shown adverse effects on linear growth, weight gain, head growth, or development in children aged 1 to 5 years subsequent to valsartan use, and it appears to be well tolerated and efficacious in reducing elevated blood pressure. Expand
Lack of pediatric drug formulations.
Presentations and publications on stable drug formulations will offer the opportunities for pediatric patients to receive the desired drugs and doses most effectively and safely. Expand
Efficacy and safety of valsartan compared to enalapril in hypertensive children: a 12-week, randomized, double-blind, parallel-group study
Valsartan and enalapril provided comparable BP reductions and effective BP control and were well tolerated in hypertensive children aged 6–17 years. Expand